PDF(Pubmed)
Abstract：
UNASSIGNED: The incidence and mortality of gynaecological cancers can significantly impact women\'s quality of life and increase the health care burden for organisations globally. The objective of this study was to evaluate global inequalities in the incidence and mortality of gynaecological cancers in 2022, based on The Global Cancer Observatory (GLOBOCAN) 2022 estimates. The future burden of gynaecological cancers (GCs) in 2050 was also projected.
UNASSIGNED: Data regarding to the total cases and deaths related to gynaecological cancer, as well as cases and deaths pertaining to different subtypes of GCs, gathered from the GLOBOCAN database for the year 2022. Predictions for the number of cases and deaths in the year 2050 were derived from global demographic projections, categorised by world region and Human Development Index (HDI).
UNASSIGNED: In 2022, there were 1 473 427 new cases of GCs and 680 372 deaths. The incidence of gynecological cancer reached 30.3 per 100 000, and the mortality rate hit 13.2 per 100 000. The age-standardised incidence of GCs in Eastern Africa is higher than 50 per 100 000, whereas the age-standardised incidence in Northern Africa is 17.1 per 100 000. The highest mortality rates were found in East Africa (ASMR (age-standardised mortality rates) of 35.3 per 100 000) and the lowest in Australia and New Zealand (ASMR of 8.1 per 100 000). These are related to the endemic areas of HIV and HPV. Very High HDI countries had the highest incidence of GCs, with ASIR (age-standardised incidence rates) of 34.8 per 100 000, and low HDI countries had the second highest incidence rate, with an ASIR of 33.0 per 100 000. Eswatini had the highest incidence and mortality (105.4 per 100 000; 71.1 per 100 000) and Yemen the lowest (5.8 per 100 000; 4.4 per 100 000). If the current trends in morbidity and mortality are maintained, number of new cases and deaths from female reproductive tract tumours is projected to increase over the next two decades.
UNASSIGNED: In 2022, gynaecological cancers accounted for 1 473 427 new cases and 680 372 deaths globally, with significant regional disparities in incidence and mortality rates. The highest rates were observed in Eastern Africa and countries with very high and low HDI, with Eswatini recording the most severe statistics. If current trends continue, the number of new cases and deaths from gynaecological cancers is expected to rise over the next two decades, highlighting the urgent need for effective interventions.
UNASSIGNED: Data regarding to the total cases and deaths related to gynaecological cancer, as well as cases and deaths pertaining to different subtypes of GCs, gathered from the GLOBOCAN database for the year 2022. Predictions for the number of cases and deaths in the year 2050 were derived from global demographic projections, categorised by world region and Human Development Index (HDI).
UNASSIGNED: In 2022, there were 1 473 427 new cases of GCs and 680 372 deaths. The incidence of gynecological cancer reached 30.3 per 100 000, and the mortality rate hit 13.2 per 100 000. The age-standardised incidence of GCs in Eastern Africa is higher than 50 per 100 000, whereas the age-standardised incidence in Northern Africa is 17.1 per 100 000. The highest mortality rates were found in East Africa (ASMR (age-standardised mortality rates) of 35.3 per 100 000) and the lowest in Australia and New Zealand (ASMR of 8.1 per 100 000). These are related to the endemic areas of HIV and HPV. Very High HDI countries had the highest incidence of GCs, with ASIR (age-standardised incidence rates) of 34.8 per 100 000, and low HDI countries had the second highest incidence rate, with an ASIR of 33.0 per 100 000. Eswatini had the highest incidence and mortality (105.4 per 100 000; 71.1 per 100 000) and Yemen the lowest (5.8 per 100 000; 4.4 per 100 000). If the current trends in morbidity and mortality are maintained, number of new cases and deaths from female reproductive tract tumours is projected to increase over the next two decades.
UNASSIGNED: In 2022, gynaecological cancers accounted for 1 473 427 new cases and 680 372 deaths globally, with significant regional disparities in incidence and mortality rates. The highest rates were observed in Eastern Africa and countries with very high and low HDI, with Eswatini recording the most severe statistics. If current trends continue, the number of new cases and deaths from gynaecological cancers is expected to rise over the next two decades, highlighting the urgent need for effective interventions.
摘要：
妇科癌症的发病率和死亡率会显著影响女性的生活质量，并增加全球组织的医疗保健负担。这项研究的目的是根据2022年全球癌症观察站（GLOBOCAN）的估计，评估2022年全球妇科癌症发病率和死亡率的不平等。还预测了2050年妇科癌症（GC）的未来负担。
■与妇科癌症相关的总病例和死亡数据，以及与不同亚型GCs有关的病例和死亡，从2022年的GLOBOCAN数据库中收集。对2050年病例和死亡人数的预测来自全球人口预测，按世界区域和人类发展指数(HDI)分类。
■2022年，有1473427例新的GCs病例和680372例死亡。妇科癌症的发病率达到30.3/100000，死亡率达到13.2/100000。东非的GCs的年龄标准化发病率高于每100000人中50人，而北非的年龄标准化发病率为每100000人中17.1人。东非的死亡率最高（ASMR（年龄标准化死亡率）为每100000人35.3），澳大利亚和新西兰的死亡率最低（ASMR为每100000人8.1）。这些与HIV和HPV的流行地区有关。非常高的人类发展指数国家的GCs发病率最高，ASIR（年龄标准化发病率）为34.8/100000，而低HDI国家的发病率第二高，ASIR为33.0/100000。埃斯瓦蒂尼的发病率和死亡率最高（105.4/100000；71.1/100000），也门最低（5.8/100000；4.4/100000）。如果保持目前的发病率和死亡率趋势，女性生殖道肿瘤的新病例和死亡人数预计将在未来二十年内增加。
■2022年，妇科癌症占全球1473427例新病例和680372例死亡。在发病率和死亡率方面存在显著的地区差异。在东非和人类发展指数很高和很低的国家观察到了最高的比率，埃斯瓦蒂尼记录了最严重的统计数据。如果目前的趋势继续下去，妇科癌症的新病例和死亡人数预计将在未来二十年内上升，强调迫切需要有效的干预措施。
■与妇科癌症相关的总病例和死亡数据，以及与不同亚型GCs有关的病例和死亡，从2022年的GLOBOCAN数据库中收集。对2050年病例和死亡人数的预测来自全球人口预测，按世界区域和人类发展指数(HDI)分类。
■2022年，有1473427例新的GCs病例和680372例死亡。妇科癌症的发病率达到30.3/100000，死亡率达到13.2/100000。东非的GCs的年龄标准化发病率高于每100000人中50人，而北非的年龄标准化发病率为每100000人中17.1人。东非的死亡率最高（ASMR（年龄标准化死亡率）为每100000人35.3），澳大利亚和新西兰的死亡率最低（ASMR为每100000人8.1）。这些与HIV和HPV的流行地区有关。非常高的人类发展指数国家的GCs发病率最高，ASIR（年龄标准化发病率）为34.8/100000，而低HDI国家的发病率第二高，ASIR为33.0/100000。埃斯瓦蒂尼的发病率和死亡率最高（105.4/100000；71.1/100000），也门最低（5.8/100000；4.4/100000）。如果保持目前的发病率和死亡率趋势，女性生殖道肿瘤的新病例和死亡人数预计将在未来二十年内增加。
■2022年，妇科癌症占全球1473427例新病例和680372例死亡。在发病率和死亡率方面存在显著的地区差异。在东非和人类发展指数很高和很低的国家观察到了最高的比率，埃斯瓦蒂尼记录了最严重的统计数据。如果目前的趋势继续下去，妇科癌症的新病例和死亡人数预计将在未来二十年内上升，强调迫切需要有效的干预措施。
